Cypher is a brand of drug-eluting coronary stent from Cordis Corporation, a Cardinal Health company. During a balloon angioplasty, the stent is inserted into the artery to provide a "scaffold" to open the artery. An anti-rejection-type medication, sirolimus, helps to limit the overgrowth of normal cells while the artery heals which reduces the chance of re-blockage in the treated area known as restenosis, and reduces the chances that another procedure is required.[1][2]

The Cypher stent was approved for use by the FDA in 2003.[2] Following claims of inconsistent manufacturing processes and poor sales, Johnson & Johnson have announced that it will stop selling Cypher stents by the end of 2011.[3]

See also

References

  1. ↑ "Learn about CYPHER Stent, the latest advance in stent technology". Cordis Corporation. Archived from the original on 2004-06-26. Retrieved 2008-04-01.
  2. 1 2 "CYPHER™ Sirolimus-eluting Coronary Stent - P020026". FDA.gov. U.S. Food and Drug Administration. Retrieved 1 Aug 2016.
  3. ↑ "J&J to quit struggling heart stent business". Reuters. 2011-06-15. Retrieved 2011-07-18.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.